A-Migel oral gel is indicated- For the treatment of oral and gastrointestinal candidiasis. For eradication of fungal colonization in the mouth and gastrointestinal tract. For the treatment of super infections due to gram-positive bacteria. A-Migel ... Read more A-Migel oral gel is indicated- For the treatment of oral and gastrointestinal candidiasis. For eradication of fungal colonization in the mouth and gastrointestinal tract. For the treatment of super infections due to gram-positive bacteria. A-Migel cream is indicated in dermatomycoses, e.g.: Tinea pedis (Athlete's foot) Tinea corporis (Tinea circinata) Tinea manuum Tinea cruris due to: Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum audouinii, Epidermophyton floccosum Candidial infections Tinea versicolor. Infections of the skin (e.g. intertrigo) Perianal infections Stomatitis angularis (cheilitis) Balanoposthitis Otitis externa In addition miconazole cream has a very rapid alleviating effect on the pruritis which frequently accompanies infection.
Pharmacodynamics : Miconazole possesses an antifungal activity against the common dermatophytes and yeasts as well as an antibacterial activity against certain gram-positive bacilli and cocci. Its activity is based on the inhibition of a demethylation step in the ergosterol biosynthesis. Ergosterol, the end-product of the biosynthetic pathway and the main sterol in yeast and fungi. The disruption in production of ergosterol disrupts the fungal cell membrane, causing holes to appear in it. These holes allow the essential constituents of the fungal cells to leak out and ultimately the fungal cells die. Pharmacokinetics : The oral bioavailability of Miconazole is low (25-30%) because there is little absorption of Miconazole from the intestinal tract. Miconazole is systemically absorbed after administration as the oral gel. Absorbed Miconazole is bound to plasma proteins (88.2%), primarily to serum albumin and red blood cells (10.6%). The absorbed portion of Miconazole oral gel is largely metabolized; less than 1% of the administered dose is excreted unchanged in the urine. The terminal plasma half-life is 20-25 hours in most patients. The elimination half-life of Miconazole is similar in any renal impaired patient.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Oropharyngeal candidosis- Infants 4-24 months : 1.25 ml (1⁄4 measuring spoon) of gel, applied 4 times day after meals. Adult and children 2 years of age and older : 2.5 ml (1⁄2 measuring spoon) of gel, applied 4 times a day after meals. Gastrointestinal tract candidosis- Infants (4 months of age or above) : Children and adults who have difficulty swallowing tablets: 20 mg per kg body weight per day, in four divided doses. The daily dose should not exceed 250 mg (10 ml gel) four times daily. Missed Dose: Apply the missed dose as soon as you remember. In case of next dosing time, omit the missed dose and continue your usual course. Miconazole Cream : Sufficient Miconazole Cream should be applied to cover affected areas twice daily (morning and evening) in patients with tinea pedis, tinea cruris, tinea corporis and cutaneous candidiasis and once daily in patients with tinea versicolor. If Miconazole Cream is used in intertriginous areas it should be applied sparingly and smoothed in well to avoid maceration effects. Early relief of symptoms (2 to 3 days) is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun.All lesions usually disappear after 2 to 5 weeks.Prolong treatment for 10 days to prevent relapse. However, Candida infections, tinea cruris and corporis should be treated for two weeks and tinea pedis for one month in order to reduce the possibility of recurrence.
Occasionally nausea and vomiting, diarrhea with long term use and rarely allergic reactions.
Miconazole is contraindicated in patients with known hypersensitivity to the active ingredient.
Concomitant treatment with Terfenadine, Astemizole and Cisapride should be avoided because in vitro studies suggest that A-Migel may inhibit their metabolism, so these products miqht precipitated. A-Migel may delay Phenytoin and Cyclosporine metabolism and this might precipitate Phenytoin and Cyclosporine toxicity, respectively.
If the concomitant use of A-Migel and anticoagulant is considered, the anti-coagulant effect should be monitored and titrated. A-Migel and phenytoin plasma level should also be monitored when used concomitantly. In infants and young children, caution must be taken to ensure that the gel does not obstruct the throat.